Related Experiment Video

Updated: Jul 22, 2026

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
11:44

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3

Published on: January 24, 2016

Identifying a common molecular mechanism for inhibition of MITF and STAT3 by PIAS3

Carmit Levy1, Yu-Nee Lee, Hovav Nechushtan

  • 1Department of Biochemistry, Hebrew University Hadassah Medical School, POB 12272, Jerusalem 91120, Israel.

Blood
|December 22, 2005
PubMed

Insights

Protein inhibitor of activated STAT3 (PIAS3) suppresses microphthalmia transcription factor (MITF) and signal transducer and activator of transcription 3 (STAT3). A specific PIAS3 motif (PIAS82-132) inhibits both transcription factors, offering potential for antioncogenic agents.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • Protein inhibitor of activated STAT3 (PIAS3) is crucial for regulating transcription factors MITF and STAT3.
  • MITF and STAT3 are key regulators of growth and function in mast cells and melanocytes.
  • Previous studies showed PIAS3 binding to MITF inhibits its transcriptional activity.

Purpose of the Study:

  • To identify the common binding motif in PIAS3 responsible for inhibiting both MITF and STAT3.
  • To understand the structural basis of PIAS3's inhibitory mechanism.
  • To explore the potential of PIAS3 as a target for antioncogenic therapies.

Main Methods:

  • Protein binding assays to identify the PIAS3 motif.
  • Functional assays to assess the inhibitory activity of the motif on MITF and STAT3.
  • Three-dimensional protein modeling to analyze the motif's structure.
  • Site-directed mutagenesis to disrupt alpha helices within the motif.

Main Results:

  • A 50-amino acid motif (PIAS82-132) within PIAS3 was identified as sufficient for inhibiting both MITF and STAT3.
  • The identified motif contains two alpha helices, with disruption of one helix abolishing PIAS3's inhibitory activity.
  • PIAS3 binding to MITF is followed by release upon cellular activation, enabling subsequent binding to STAT3.

Conclusions:

  • The PIAS82-132 motif is essential for PIAS3's dual inhibitory function on MITF and STAT3.
  • Structural integrity of the alpha helices within this motif is critical for its activity.
  • These findings provide insights into PIAS3's mechanism and suggest its potential as a therapeutic target for inhibiting STAT3 and MITF in cancer.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry08:07

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry

Published on: July 26, 2019

Related Concept Videos

Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...